Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
Authors:
Open Access
- 23 October 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (24) , 9365-9372
Abstract
DNA damage response (DDR) gene alterations in cancer are associated with a higher tumor mutational burden (TMB) and may impact clinical outcomes of urothelial cancer (UC). Here, we explore the prognostic role of DDR alterations in advanced UC treated with anti‐PD‐1/PD‐L1 agents. The study included 53 patients who had FoundationOne genomic sequencing and received anti‐PD‐1/PD‐L1 therapy. Fisher exact test and trend test were used to assess differences in objective response rate (ORR). Overall survival (OS) was measured from the time of initial UC diagnosis and Cox proportional hazard regression analysis was performed to calculate hazard ratio (HR) and 95% confidence interval (CI). The cohort had a median age of 66 with 64% receiving platinum‐based chemotherapy. DDR alterations (including ATM) were associated with a non‐significantly higher ORR to PD‐1/PD‐L1 blockade (41% vs. 21%, p = 0.136). Patients with DDR alterations (excluding ATM) had non‐significantly longer OS, likely due to a small sample size (HR = 0.53, 95% CI 0.20–1.38, p = 0.19). ATM alterations were associated with a non‐significantly higher ORR (40% vs. 29%, p = 0.6), but also with significantly shorter OS (HR = 5.7, 95% CI 1.65–19.74, p = 0.006). Patients with ≥ 3 DDR alterations (including ATM) had substantially higher TMB (p = 0.01) and higher ORR (80%) with PD‐1/PD‐L1 blockade versus 24% ORR in patients with ATM alterations were associated with shorter OS.Keywords
This publication has 26 references indexed in Scilit:
- Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder CarcinomaJAMA Oncology, 2016
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyAnnals of Oncology, 2016
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerEuropean Urology, 2015
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transitionNature Communications, 2015
- The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defectInternational Journal of Radiation Biology, 2015
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancerNature Reviews Molecular Cell Biology, 2008
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005